Prescriber's Corner

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Amber C. King, PharmD, BCOP, and Jennifer S. Orozco, PharmD

Department of Clinical Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York

Authors’ disclosures of conflicts of interest are found at the end of this article.

Amber C. King, PharmD, BCOP, Memorial Sloan Kettering Cancer Center—Clinical Pharmacy, 1275 York Avenue, New York, New York 10065. E-mail: kinga@mskcc.org


J Adv Pract Oncol 2019;10(8):878–882 | https://doi.org/10.6004/jadpro.2019.10.8.9 | © 2019 Harborside™


  

ABSTRACT

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy in relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients who have had suboptimal responses to conventional therapies. The immune activation that confers the efficacy of axi-cel comes at the price of potentially devastating adverse phenomena: cytokine release syndrome and neurotoxicity. This article serves as an overview of axi-cel, including a review of the available clinical evidence, mechanism of action, and management of some of the unique toxicities of axi-cel. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.